Introduction {#s1}
============

Around 1 in 10 infants is born preterm, and survival of these infants has increased significantly over the last two decades ([@B1], [@B2]). However, brain injury, associated with two different patterns of damage, periventricular leukomalacia (PVL) and intraventricular hemorrhage (IVH), is common in infants born preterm, with potentially devastating personal impacts and significant population effects. While the risk of PVL in infants below 32 weeks has halved over the last two decades, the risk of IVH has stayed similar despite improvements in antenatal and neonatal care and while new interventions, such as delayed cord clamping, antenatal steroids, and intrapartum care, appear to reduce the risk of IVH, the overall risk of IVH remains high ([@B3]--[@B6]).

Consequently, it now represents the most common cause of neurological disability in the survivors ([@B7]). Those infants who develop severe intraventricular hemorrhage (sIVH) are at high risk of developing post-hemorrhagic ventricular dilatation (PHVD), a condition with high rates of long-term disability with conditions such as cerebral palsy (CP), sensory problems, and cognitive deficits ([@B8], [@B9]). In addition to the personal impact, the care of these premature infants who grow up with potentially disabling brain injury is expensive, with economic impacts to health care, the families involved, educational systems, and society at large ([@B10], [@B11]).

However, while reducing neonatal brain injury remains a research priority, no standardized treatment for these vulnerable infants appears to exist, although a number of treatments designed to prevent ongoing brain injury after sIVH and subsequent PHVD have been studied ([@B12]--[@B26]). This work aims to use Network Meta-analysis (NMA) methodology to allow the comparison of different treatment modalities for PHVD, combining the direct evidence of comparisons trailed, and deriving indirect assessments to help identify the most efficacious treatment. To our knowledge, NMA has not been applied to interventions targeted at preventing the complications and the neurodevelopmental sequelae after development of PHVD.

Methods and Materials {#s2}
=====================

Study Selection and Data Collection
-----------------------------------

Criteria for inclusion were based on previous meta-analyses in this area and methodology was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@B27]--[@B30]). Systematic review was performed by all three authors using PubMed (1966--2018), EMBASE (1974--2018), and the Cochrane Library. A free-word search was performed ([Appendix 1](#SM1){ref-type="supplementary-material"}) to identify likely relevant literature. The search strategy was piloted to ensure that it identified studies already known by the authors to be relevant. Searches were limited to those with English language abstracts and for research in human subjects.

Three quantitative analyses were of interest: (i) death, (ii) neurodevelopmental disability, and (iii) ventriculo-peritoneal shunt surgery. The titles obtained from database searching were sifted to exclude duplicates and those clearly not relevant to the review. Abstracts of those remaining were examined and tested against the inclusion criteria.

-   Randomized or quasi-randomized controlled trials for the treatment of PHVD

-   At least one measure out of ◦ Neurodevelopmental outcomes at or beyond 12 months of age◦ Mortality◦ Ventriculo-peritoneal shunt surgery

-   Randomized or quasi-randomized intervention trials

Full texts were obtained for those articles likely to be eligible and reviewed once more. The process was performed independently by all three authors. References in the papers were checked to identify any other possible relevant studies. Data were extracted on the characteristics of the individual studies. All three authors independently reviewed the papers identified and confirmed eligibility and the quality rating. Studies were assessed on a quality rating of adequate, unclear, or inadequate on the categories of random allocation, concealment, and blinding. Primary outcome measure was death or moderate or severe neurodevelopmental outcome at or beyond 12 months of corrected age (using any standardized measure). Where developmental outcomes were reported in a number of papers, the reported primary outcome of the study was used. An arbitrary control group was defined as treatment for PHVD only being instigated once head growth was excessive or there were clinical signs or raised intracranial pressure mandating treatment. Other interventions were grouped by consensus by two of the authors prior to analyses being performed (DO and DH). Intention-to-treat analysis was used where available. All three authors assessed the risk of bias in trials using the Cochrane risk of bias tool, with discrepancies resolved by consensus ([@B31]). Where composite outcomes of death and/or VP shunt or disability were not provided, they were calculated if possible from the presented data. Where data were unavailable, we assumed that infants who died before discharge from the neonatal unit did not receive VP shunts. Authors of included papers were not approached for missing data or where queries about a studies\' methodology due to the length of time since the publications of many of the manuscripts included.

Statistical Analysis
--------------------

Network mapping was performed with the size of the nodes proportional to the sample size and the thickness of the connecting lines proportional to the number of trials. We then performed a Bayesian random-effects model using the Markov chain Monte Carlo method. The results were reported as OR with 95% confidence intervals. We used *p* \< 0.05 as a conventional level of significance. The areas under the cumulative ranking curve (SUCRA) were calculated as a measure of the probability that each intervention was the best for each of the outcome measures, and for the primary outcome, we also derived the probabilities that each therapy is likely to be the 1st, 2nd, 3rd, etc. best therapy ([@B32]).

Analyses were repeated for the following outcomes:

1.  Death or moderate or severe neurodevelopmental impairment at or beyond 12 months of age

2.  Moderate or severe neurodevelopmental impairment at or beyond 12 months of age

3.  Death in the neonatal period, or before 1 year of age

4.  Requiring ventriculo-peritoneal shunt surgery in the neonatal period, or before 1 year of age

5.  Requiring ventriculo-peritoneal shunt surgery or death in the neonatal period, or before 1 year of age

An assumption behind multiple-treatment meta-analysis is that direct and indirect evidence on comparisons do not disagree (coherence). To estimate this, we planned to calculate the direct and indirect OR where possible; however, due to the limited amount of studies reporting the primary outcome, we were unable to test if the direct and indirect assessments were coherent.

Finally, an *a priori* sensitivity analysis was planned excluding those studies that were considered "inadequate" on any quality measures. All analyses were performed using Stata 14. Results are presented as OR (95% confidence interval).

Public and Patient Involvement
------------------------------

Patients or members of the public were not involved in the design, or conduct, reporting, or dissemination plan of this research.

Results {#s3}
=======

Literature Search
-----------------

Databases were searched on 10/09/2018 and, after removal of duplicates, produced a list of 3445 publications. Of these, 36 abstracts were screened, and of these, a total of 11 full-text papers were reviewed, all of which fulfilled the inclusion criteria ([@B13], [@B14], [@B16]--[@B22], [@B24], [@B25]). Four systematic reviews were identified ([@B27], [@B29], [@B33], [@B34]) and a further three likely papers were identified from the references of the full-text papers and the existing reviews. These three additional papers were reviewed and all were included in the analysis, leaving a total of 14 papers \[[Appendix 2](#SM2){ref-type="supplementary-material"}; ([@B13]--[@B26])\] from 10 different trials. The earliest publication dates were from 1980 ([@B15]), and the most recent dates were from 2019 ([@B20]). Overall, 700 individuals were randomly assigned and were included in at least one multiple-treatment meta-analysis, although only 449 infants have been enrolled in trials that have reported the primary outcome. All studies were two-armed trials. Further details are shown in [Appendix 3](#SM3){ref-type="supplementary-material"}.

Six categories of intervention were identified by the authors:

1.  Control (defined as above) ([@B13]--[@B17], [@B19]--[@B21], [@B23]--[@B26])

2.  Tapping of CSF prior to symptoms or excessive head growth ([@B16], [@B17])

3.  Diuretic therapy ([@B23]--[@B25])

4.  Drainage Irrigation and Fibrinolytic Therapy (DRIFT) ([@B13], [@B18], [@B19])

5.  Fibrinolytic therapy ([@B21], [@B22])

After discussion between authors regarding one paper randomizing infants between CSF tapping at conventional levels (2 above) and early tapping, and an additional category was added ([@B6]) (Early CSF tapping) to accommodate this intervention ([@B20]).

A total of four studies reported an eligible neurodevelopmental measure ([@B13], [@B19], [@B24]--[@B26]), while all reported mortality or shunt usage during the neonatal period or during the first year of life. Five studies were European ([@B13], [@B17], [@B20], [@B22], [@B24]), four were based in the USA ([@B14], [@B15], [@B23], [@B26]), and 1 was based in Turkey ([@B21]). All studies use some form of imaging to diagnose IVH. All studies but two had a control group compatible with our pre-defined criteria; Luciano, in contrast, randomized between diuretic treatment in one arm and streptokinase in the other ([@B22]) and De Vries used two different thresholds of CSF tapping (discussed above) ([@B20]). One study ([@B15]) used an alternative number to allocate treatment arms, while a further three did not specify the randomization methods ([@B21], [@B23], [@B35]). VP shunt criteria were defined in all studies except two ([@B15], [@B21]). Of the four trials that reported neurodevelopmental data, three were considered adequate ([@B13], [@B16], [@B17], [@B19], [@B24], [@B25]) and one was unclear ([@B26]). No trial was able to blind clinicians to the intervention. A summary of quality assessments is shown in [Figure 1](#F1){ref-type="fig"}.

![Quality measures.](fped-08-00238-g0001){#F1}

Individual Study Findings
-------------------------

Two studies investigated the use of furosemide and acetazolamide vs. standard treatment/LPs. Libenson ([@B23]) included a total of 16 infants who received either acetazolamide and frusemide, or daily LPs. They reported a reduction in VP shunts (10 vs. 50%) although there was crossover between treatment arms. Kennedy et al. ([@B24], [@B25]) also compared acetazolamide and frusemide to a control group and reported a higher rate of death and/or ventricular shunt placement in the intervention arm \[RR 1.42 (1.06--1.90); *p* = 0.026\] and worse developmental outcomes \[e.g., RR 1.67 (1.23--2.28) for motor impairment\]. Mantovani et al. ([@B15]), Dykes et al. ([@B26]), Anwar et al. ([@B14]), and the Ventriculomegaly Trial Group ([@B16]) compared frequent LP to conservative treatment, but none reported a difference in VP shunts or death between these treatment arms. De Vries et al. ([@B20]) randomized 126 infants with PHVD to intervention of repeat CSF tapping to two different thresholds with no difference in the primary outcome of VP shunt or death (*p* = 0.45). Two small studies have investigated the use of intraventricular streptokinase; Luciano et al. ([@B22]) found no difference in the rate of VP shunt between the two groups while Yapicioglu et al. ([@B21]) reported an increased need for VP shunt in the streptokinase group (83 vs. 50%). Finally, the DRIFT study included a total of 70 infants who were randomized to either intraventricular drainage, irrigation, and fibrinolytic therapy with tissue plasminogen activator (DRIFT) or to standard treatment ([@B13]). This study was closed early due a minimum chance that the short-term primary outcome would identify a difference between groups (VP shunt or death). There was no difference in the primary outcome of reducing the rates of VP shunt surgery or death but an analysis of developmental outcomes in infants at 2 years corrected age found evidence of improved neurodevelopment \[adjusted OR of 0.17 (0.05--0.57)\].

Quantitative Synthesis
----------------------

[Figure 2](#F2){ref-type="fig"} shows the resultant network of eligible comparisons from the multiple-treatment meta-analysis.

![Network eligible comparisons for the multiple-treatment meta-analysis.](fped-08-00238-g0002){#F2}

Of the 15 possible pair comparisons, 6 have been studied directly. [Table 1](#T1){ref-type="table"} summarizes the results of the multiple-treatment meta-analysis for the pre-specified outcomes \[e.g., compared to control diuretics, which appeared to have a higher OR of the primary outcome (OR 1.17 (0.99--1.39)\], while compared to diuretics, DRIFT had a lower OR \[OR 0.69 (0.44--1.07)\]. Repeating the analysis for the other outcomes showed similar results. No comparison reached conventional levels of statistical significance.

###### 

Comparisons between different treatment groups for direct and indirect outcome measures.

  **Treatment comparison**            **Moderate or severe neuro-disability, or death**   **Moderate or severe neuro-disability**   **VP shunt or death**   **VP shunt**   **Death**                                                                    
  ----------------------------------- --------------------------------------------------- ----------------------------------------- ----------------------- -------------- ------------------- ------- ------------------- ------- -------------------- -------
  **Compared to Control**                                                                                                                                                                                                                               
  CSF removal                         1.01 (0.86--1.19)                                   0.921                                     0.87 (0.45--1.70)       0.689          0.96 (0.8--1.15)    0.652   0.97 (0.75--1.24)   0.791   0.91 (0.53--1.57)    0.739
  Diuretics                           1.17 (0.99--1.39)                                   0.062                                     1.05 (0.47--2.34)       0.905          1.20 (0.93--1.54)   0.165   1.07 (0.79--1.44)   0.676   1.58 (0.81--3.08)    0.179
  DRIFT                               0.80 (0.53--1.22)                                   0.302                                     0.87 (0.35--2.17)       0.759          0.97 (0.62--1.53)   0.91    1.04 (0.6--1.79)    0.89    0.58 (0.15--2.28)    0.439
  Early CSF removal                                                                                                                                                        0.80 (0.47--1.37)   0.421   0.80 (0.39--1.67)   0.556   0.77 (0.26--2.32)    0.645
  Fibrinolytics                                                                                                                                                            1.20 (0.52--2.77)   0.675   1.41 (0.70--2.84)   0.342   1.26 (0.20--7.76)    0.806
  **Compared to CSF Removal**                                                                                                                                                                                                                           
  Diuretics                           1.16 (0.92--1.47)                                   0.20                                      1.20 (0.42--3.42)       0.73           1.25 (0.91--1.70)   0.16    1.1 (0.75--1.63)    0.62    1.73 (0.73--4.10)    0.21
  DRIFT                               0.80 (0.51--1.24)                                   0.32                                      0.99 (0.32--3.09)       0.99           1.02 (0.62--1.65)   0.95    1.07 (0.59--1.96)   0.81    0.64 (0.15--2.78)    0.55
  Early CSF removal                                                                                                                                                        0.84 (0.51--1.39)   0.49    0.83 (0.42--1.65)   0.60    0.85 (0.33--2.20)    0.73
  Fibrinolytics                                                                                                                                                            1.25 (0.53--2.94)   0.61    1.45 (0.69--3.07)   0.33    1.38 (0.21--9.22)    0.74
  **Compared to Diuretic**                                                                                                                                                                                                                              
  DRIFT                               0.69 (0.44--1.07)                                   0.10                                      0.82 (0.24--2.79)       0.76           0.81 (0.48--1.37)   0.44    0.97 (0.52--1.82)   0.94    0.37 (0.08--1.68)    0.20
  Early CSF removal                                                                                                                                                        1.49 (0.37--1.21)   0.19    0.75 (0.34--1.66)   0.48    0.49 (0.14--1.77)    0.28
  Fibrinolytics                                                                                                                                                            1.00 (0.45--2.23)   1.00    1.32 (0.64--2.71)   0.45    0.80 (0.13--4.91)    0.81
  **Compared to DRIFT**                                                                                                                                                                                                                                 
  Early CSF removal                                                                                                                                                        0.82 (0.41--1.66)   0.59    0.77 (0.31--1.92)   0.58    1.32 (0.23--7.59)    0.76
  Fibrinolytics                                                                                                                                                            1.23 (0.47--3.19)   0.67    1.35 (0.56--3.29)   0.51    2.15 (0.22--20.84)   0.51
  **Compared to Early CSF Removal**                                                                                                                                                                                                                     
  Fibrinolytics                                                                                                                                                            1.49 (0.55--4.04)   0.43    1.75 (0.63--4.83)   0.28    1.63 (0.19--13.62)   0.65

[Table 2](#T2){ref-type="table"} and [Figure 3](#F3){ref-type="fig"} shows the SURCRA for each treatment and outcomes measured. DRIFT had the highest probability of being the best treatment for the primary outcome (82.1%), followed by CSF removal (10.8%), conservative management (6.7%), and then diuretic therapy (0.4%). No study was able to blind clinicians delivering the treatment, and so no additional analysis was performed.

###### 

SUCRA for probability of most efficacious treatment for different outcomes.

  **Treatment**        **Outcome**                     
  -------------------- ------------- ----- ----- ----- -----
  Control              0.6           0.4   0.5   0.5   0.5
  CSF removal          0.5           0.6   0.6   0.6   0.6
  Diuretic treatment   0.1           0.4   0.2   0.4   0.2
  DRIFT                0.9           0.6   0.8   0.5   0.6
  Early CSF removal    --            --    0.6   0.7   0.8
  Fibrinolytics        --            --    0.4   0.2   0.3

![Probabilities of each therapy being the 1st, 2nd, 3rd, or 4th best treatment for the prevention of moderate/severe neuro-disability or death.](fped-08-00238-g0003){#F3}

Discussion {#s4}
==========

We have found in this work that little evidence exists to directly differentiate any proposed or trialed therapy for PHVD. Diuretic therapy appeared to be detrimental, and ranking of therapies appeared to show that DRIFT may by the most efficacious. However, despite the significant impact of this disease, only 700 infants have ever been enrolled in an intervention trial, and further studies are desperately needed.

Limitations of this work include the heterogeneity of the infants enrolled, in part due to the wide time frame recruitment across the studies (1980--2019). Neonatal care has changed significantly during this time, with new therapies such as antenatal steroids and surfactant, and the reduction in other treatments such as postnatal steroids. Despite this, the control arm of these trials appears remarkably similar over the 40 years investigated, with VP shunt insertion after development of PHVD still the standard treatment of choice. The biggest and perhaps most influential trials have all been performed in the last 20 years and had infants of similar gestation, with similar control group interventions. We have used a random effects model to allow for increased uncertainty in this work, but the lack of precision is likely due to the small numbers included (around 700 infants involved in these randomized controlled trials) rather than heterogeneity.

The timing of intervention in each study makes the comparison of treatments in this using this methodology difficult. For example, in some of the trials, lumbar punctures were used to reduce the size of already distended ventricles compared ([@B13]) to preventing further enlargement through early intervention ([@B23]). The differences in the randomization thresholds may contribute to some of the variation seen in the outcome measured (e.g., the percentage of VP shunts required).

PHVD remains a significant problem in the developed world. There are around 8,000 preterm infants born 32 weeks gestation in England alone each year, and around 483 (6%) of these develop a sIVH ([@B7]). Overall, around 700 infants a year develop sIVH after birth, and most of these will develop some degree of motor or cognitive disability ([@B13]). In all the work reviewed here, mortality was high, and many infants who survive have complex developmental needs, a population impact likely higher than neonatal hypoxic--ischemic encephalopathy ([@B36]) or Trisomy 21 ([@B37]), with a corresponding burden to the NHS (in future healthcare needs) and society. With this in mind, we find the lack of recent trials disappointing, and this appears to be a vital area for new biomedical research.

In this work, DRIFT is likely to be the most efficacious treatment. Recent presentation of a secondary analysis of school age neurodevelopmental outcomes from this trial appears to show similar results to those used in this work on a subset of the initial trial group ([@B38]). While this recent work was a secondary analysis, the results are in parallel with those at 2 years, with children assessed at 10 years, after adjusting for gender, birthweight, and grade of IVH, with cognitive quotient being, on average, 23.47 points higher than those who received standard treatment (*p* = 0.009).

DRIFT is however a complex intervention and involves 72 h of intensive nursing and medical care. The process of DRIFT was modified during the trial due to concerns over secondary bleeds, and the trial was stopped early due to likely futility in reaching a difference in the short-term primary outcome of shunt or death. As an alternative approach, some units have reported success with more rapid clot removal (e.g., through endoscopes) or percutaneous methods of treating intra- and extra-axial intracranial hemorrhage, although no RCT has yet been published with these novel treatments ([@B39], [@B40]). Equally, the ELVIS trial ([@B20]) has completed its recruitment and later neurodevelopmental outcomes are expected to be published soon. These results are eagerly awaited as a sub-study of the ELVIS trial has reported that, in the high-threshold group (LPs when the VI \> p97 + 4 mm and anterior horn width \>10 mm), there was more brain injury and higher ventricular volumes compared to the low-threshold groups (VI \> p97 and anterior horn width \>6 mm) ([@B41]). There is also interest surrounding stem cell treatment after sIVH; however, this has only been reported in phase 1 trial ([@B42]). In lieu of the results of this research, [Figure 4](#F4){ref-type="fig"} shows a proposed strategy for PHVD.

![Proposed strategy for the management of PHVD.](fped-08-00238-g0004){#F4}

PHVD is a significant cause of death and disability in developed countries, yet few therapeutic options have so far been trialed. Only 700 infants have been enrolled in intervention trials, while \<500 have had longer-term developmental measures reported. While new therapies are urgently needed for these infants, at present, NMA shows that DRIFT appears to be the most likely candidate to improve outcomes after sIVH, but further work is needed to implement this in routine healthcare and promising newer therapies remain untrialed.
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